BeyondSpring Inc.: completes sale of BeyondSpring Ltd.

What happened BeyondSpring Inc reported that on Sep 30, 2026 it "completed the closing" under the Share Purchase and Collaboration Agreement dated Sep 28, 2026 and "sold and transferred" the entire issued share capital in BeyondSpring Ltd. to Biolin Investment Limited. The sale transferred the Company’s direct ownership of the BVI subsidiary that indirectly held interests in Dalian Wanchunbulin Pharmaceuticals Ltd. ("Bulin"). The filing states that no cash consideration was paid at the closing and that the investor’s obligation to conduct and complete the China portion of DUBLIN-4 constituted the non-cash consideration. The Company will receive access to clinical data generated from the China portion of the ongoing trial. The Company filed unaudited pro forma financial information giving effect to the sale.

Key details

• Closing date: Sep 30, 2026; Purchase and Collaboration Agreement dated Sep 28, 2026.
• Parties: BeyondSpring Inc. (the Company), Dalian Wanchunbulin Pharmaceuticals Ltd. ("Bulin"), and Biolin Investment Limited (the Investor).
• Asset sold: entire issued share capital of BeyondSpring Ltd., a BVI company and direct wholly owned subsidiary that indirectly held interests in Bulin.
• Consideration: no cash paid; non-cash consideration was the Investor’s obligation to conduct and complete the China portion of DUBLIN-4 and related actions by Bulin. The Company will receive access to clinical data from that China portion.
• The Company filed unaudited pro forma condensed consolidated financial information reflecting the sale.

Why it may matter The filing reports Item 2.01 (completion of acquisition or disposition of assets) describing the completed sale of a direct subsidiary and the non-cash consideration tied to conduct of the China portion of the DUBLIN-4 trial. The filing also reports Item 9.01 (financial statements and exhibits) by providing unaudited pro forma financial information for the Company giving effect to the sale. This filing does not show why the insider traded or why the company acted.